

ed to better understand the crash risk associated with prescription medications.

Drug-impaired drivers are difficult for police to detect and enforcement of current drug driving laws is difficult.

Doctors of BC encourages the governments of BC and Canada to promote and provide funding for the development of improved screening tools to detect drug-impaired drivers and to work with stakeholders to improve legislation and policies to address the problem of drug-impaired driving.

—**Jeff Brubacher, MD**
Emergency Medical Services Committee

References

1. Beasley EE, Beirness DJ. Alcohol and drug use among drivers following the introduction of immediate roadside prohibitions in British Columbia: Findings from the 2012 roadside survey. Accessed 27 February 2015. www.pssg.gov.bc.ca/osmv/data/index.htm.
2. Brubacher JR, Chan H, Martz W, et al. Recent drug use in injured British Columbia drivers. Presented at the Canadian Multidisciplinary Road Safety Conference, Vancouver, BC, 12 July 2014.
3. Ramaekers JG, Berghaus G, van Laar M, et al. Dose related risk of motor vehicle crashes after cannabis use. *Drug Alcohol Depend* 2004;73:109-119.

4. Maxwell HG, Dubois S, Weaver B, et al. The additive effects of alcohol and benzodiazepines on driving. *Can J Public Health* 2010;101:353-357.
5. Hartman RL, Huestis MA. Cannabis effects on driving skills. *Clin Chem* 2013; 59:478-492.
6. Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: Systematic review of observational studies and meta-analysis. *BMJ* 2012;344:e536.
7. Drummer OH, Gerostamoulos J, Batziris H, et al. The involvement of drugs in drivers of motor vehicles killed in Australian road traffic crashes. *Accid Anal Prev* 2004;36:239-248.
8. Laumon B, Gadegebeku B, Martin JL, et al. Cannabis intoxication and fatal road crashes in France: Population based case-control study. *BMJ* 2005;331: 1371.
9. Rapoport MJ, Lanctot KL, Streiner DL, et al. Benzodiazepine use and driving: A meta-analysis. *J Clin Psychiatry* 2009; 70:663-673.
10. Orriols L, Philip P, Moore N, et al. Benzodiazepine-like hypnotics and the associated risk of road traffic accidents. *Clin Pharmacol Ther* 2011;89:595-601.
11. Orriols L, Salmi LR, Philip P, et al. The impact of medicinal drugs on traffic safety: A systematic review of epidemiological studies. *Pharmacoepidemiol Drug Saf* 2009;18:647-658.

When to bill fee item 15142 versus 15130

It has come to the attention of the Patterns of Practice Committee that physicians may be inappropriately billing fee item 15142 (urinalysis—complete diagnostic, semi-quant, and micro) due to misinformation from medical supply company reps or colleagues.

Physicians are being told that if they purchase the more expensive strip they can bill the higher fee, 15142. This is incorrect.

In order to bill fee item 15142, you need a microscope and you must do the microscopy as well as record the results in the medical record. If you are only doing a dipstick, you should be billing fee item 15130 (urinalysis—chemical or any part of [screening]) and, of course, still recording the results.

—**Keith J. White, MD**
Chair, Patterns of Practice Committee

This article is the opinion of the Patterns of Practice Committee and has not been peer reviewed by the BCMJ Editorial Board. For further information contact Juanita Grant, audit and billing advisor, Physician and External Affairs, at 604 638-2829 or jgrant@doctorsofbc.ca.



A Doctors of BC Club MD Partner
Counterfeit-Resistant Prescription Pads and Paper

Save 15%

20 Customized Pads for only \$76.65!
2000 EMR Sheets for only \$154.82!

Email: info@rxsecurity.com

Tel: 1.800.667.9723

Now we're here for you 24 hrs a day, seven days a week.

Call at 1-800-663-6729 or visit www.physicianhealth.com.

